Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

Bio-Thera-Partnered Starjemza Becomes Eighth Stelara Rival To Be Approved By FDA

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Hikma will have one of eight approved Stelara biosimilars (Shutterstock)
Key Takeaways
  • Hikma is set to enter the US biosimilars market after its Bio-Thera-partnered Starjemza (ustekinumab-hmny) rival to Stelara was approved by the US FDA.

Hikma is getting ready to make its first launch into the US biosimilars market after receiving US Food and Drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Business